Can antibody infusions shield CLL patients from deadly infections?
NCT ID NCT04502030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether regular infusions of Panzyga (a concentrated antibody solution from donated blood) could prevent serious infections in people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. The trial included 247 adults with CLL who were receiving cancer treatment. Half got Panzyga, half got a placebo. The goal was to see if Panzyga reduced the number of major infections requiring hospitalization or leading to death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Panzyga (a human antibody solution given intravenously)
What this could lead to
If it works, this could give CLL patients a way to prevent serious infections while on cancer treatment.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The benefit may be modest, and IVIG infusions can cause side effects like headache, fever, or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Octapharma Research Site
St. Petersburg, Florida, 33709, United States
-
Octapharma Research Site
Columbus, Georgia, 31904, United States
-
Octapharma Research Site
Macon, Georgia, 31201, United States
-
Octapharma Research Site
New Orleans, Louisiana, 70112, United States
-
Octapharma Research Site
Baltimore, Maryland, 21201, United States
-
Octapharma Research Site
Baltimore, Maryland, 21205, United States
-
Octapharma Research Site
Detroit, Michigan, 48093, United States
-
Octapharma Research Site
Rochester, Minnesota, 55902, United States
-
Octapharma Research Site
Buffalo, New York, 14260, United States
-
Octapharma Research Site
New York, New York, 10032, United States
-
Octapharma Research Site
New York, New York, 10065, United States
-
Octapharma Research Site
Shirley, New York, 11967, United States
-
Octapharma Research Site
Durham, North Carolina, 27710, United States
-
Octapharma Research Site
Charleston, South Carolina, 29414, United States
-
Octapharma Research Site
Houston, Texas, 77090, United States
-
Octapharma Research Site
Brno, 625 00, Czechia
-
Octapharma Research Site
Hradec Králové, 500 05, Czechia
-
Octapharma Research Site
Ostrava, 70852, Czechia
-
Octapharma Research Site
Aalborg, 9000, Denmark
-
Octapharma Research Site
Herning, 7400, Denmark
-
Octapharma Research Site
Roskilde, 4000, Denmark
-
Octapharma Research Site
Dortmund, 44263, Germany
-
Octapharma Research Site
Frankfurt, 15236, Germany
-
Octapharma Research Site
Kiel, 24105, Germany
-
Octapharma Research Site
Marburg, 35037, Germany
-
Octapharma Research Site
Athens, 10676, Greece
-
Octapharma Research Site
Athens, 11526, Greece
-
Octapharma Research Site
Athens, 12462, Greece
-
Octapharma Research Site
Ioannina, 45500, Greece
-
Octapharma Research Site
Pátrai, 26500, Greece
-
Octapharma Research Site
Thessaloniki, 57010, Greece
-
Octapharma Research Site
Budapest, 1088, Hungary
-
Octapharma Research Site
Debrecen, 4032, Hungary
-
Octapharma Research Site
Győr, 9023, Hungary
-
Octapharma Research Site
Kaposvár, 7400, Hungary
-
Octapharma Research Site
Nyíregyháza, 4400, Hungary
-
Octapharma Research Site
Haifa, 3109601, Israel
-
Octapharma Research Site
Haifa, 34362, Israel
-
Octapharma Research Site
Petah Tikva, 49100, Israel
-
Octapharma Research Site
Castelfranco Veneto, 31033, Italy
-
Octapharma Research Site
Milan, 20132, Italy
-
Octapharma Research Site
Milan, 20162, Italy
-
Octapharma Research Site
Modena, 41124, Italy
-
Octapharma Research Site
Orbassano, 10043, Italy
-
Octapharma Research Site
Padova, 35129, Italy
-
Octapharma Research Site
Pescara, 65124, Italy
-
Octapharma Research Site
Reggio Calabria, 89133, Italy
-
Octapharma Research Site
Rome, 00161, Italy
-
Octapharma Research Site
Torino, 10126, Italy
-
Octapharma Research Site
Bialystok, 15-732, Poland
-
Octapharma Research Site
Bydgoszcz, 85-065, Poland
-
Octapharma Research Site
Gdansk, 80-214, Poland
-
Octapharma Research Site
Gdansk, 80-219, Poland
-
Octapharma Research Site
Gdynia, 81-519, Poland
-
Octapharma Research Site
Katowice, 40-519, Poland
-
Octapharma Research Site
Legnica, 59-220, Poland
-
Octapharma Research Site
Lodz, 93-513, Poland
-
Octapharma Research Site
Torun, 87-100, Poland
-
Octapharma Research Site
Warsaw, 02-776, Poland
-
Octapharma Research Site
Wroclaw, 50-367, Poland
-
Octapharma Research Site
Barnaul, 656024, Russia
-
Octapharma Research Site
Kemerovo, 650066, Russia
-
Octapharma Research Site
Moscow, 115478, Russia
-
Octapharma Research Site
Moscow, 125284, Russia
-
Octapharma Research Site
Nizhny Novgorod, 603126, Russia
-
Octapharma Research Site
Novosibirsk, 630051, Russia
-
Octapharma Research Site
Petrozavodsk, 185019, Russia
-
Octapharma Research Site
Rostov-on-Don, 344037, Russia
-
Octapharma Research Site
Saint Petersburg, 191024, Russia
-
Octapharma Research Site
Samara, 443079, Russia
-
Octapharma Research Site
Tomsk, 634063, Russia
-
Octapharma Research Site
Tula, 300053, Russia
-
Octapharma Research Site
Ufa, 450008, Russia
-
Octapharma Research Site
Yekaterinburg, 620102, Russia
-
Octapharma Research Site
Madrid, 28034, Spain
-
Octapharma Research Site
Madrid, 28040, Spain
-
Octapharma Research Site
Madrid, 28046, Spain
-
Octapharma Research Site
Oviedo, 33011, Spain
-
Octapharma Research Site
Santander, 39008, Spain
-
Octapharma Research Site
Ankara, 65900, Turkey (Türkiye)
-
Octapharma Research Site
Antalya, 7050, Turkey (Türkiye)
-
Octapharma Research Site
Istanbul, 34093, Turkey (Türkiye)
-
Octapharma Research Site
Izmir, 35100, Turkey (Türkiye)
-
Octapharma Research Site
Kayseri, 38039, Turkey (Türkiye)